Table 4

Bone status (bone mineral density, BMD) of premenopausal female patients with Graves' disease compared to both healthy controls and patients with Hashimoto's thyroiditis on stable levothyroxine replacement.

Controls

Graves' disease Months after diagnosis

Hashimoto's thyroiditis

Study points (months)

Baseline

18 ± 3

36 ± 3

Number

19

32

18

whole body BMD

Z-score

0.3

-0.2^#

-0.1**

0.1**

0.2^NS

(-0.1 - 0.7)

(-0.5 - 0.1)

(-0.7 - 0.5)

(-0.5-0.6)

(-0.2 - 0.5)

T-score

0.1

-0.5^NS

-0.1**

-0.3**

-0.1 ^NS

(-0.4 - 0.5)

((-0.9) - (-0.1))

(-0.7 - 0.5)

(-0.9 - 0.3)

(-0.4 - 0.3)

Lumbar spine BMD

Z-score

0.6

-0.1 ^NS

0.5**

0.6**

0.3 ^NS

(0.1-1.2)

(-0.6 - 0.6)

(-0.3 - 1.2)

(-0.4 - 1.6)

(-0.2 - 0.8)

T-score

0.1

-0.7 ^NS

0.1**

-0.2**

-0.4 ^NS

(-0.5 - 0.8)

((-1.4) - (-0.1))

(-0.8 - 0.9)

(-1.3 - 0.9)

(-0.9 - 0.1)

Femoral neck BMD

0.91

0.83 ^NS

0.91*

0.84*

0.86 ^NS

(0.84-0.98)

(0.77-0.90)

(0.8-1.0)

(0.75-0.94)

(0.82-0.90)

Z-score

0.5

-0.2^#

0.3**

0.1**

0.1 ^NS

(0.04-0.95)

(-0.5 - 0.3)

(-0.3 - 0.9)

(-0.5 - 0.6)

(-0.4 - 0.5)

-

T-score

-0.1

-0.6 ^NS

0.1**

-0.6*

-0.5 ^NS

(-0.6 - 0.5)

((-1.1) - (-0.1)) -

(-0.6 - 0.7)

(-1.3 - 0.2)

((-0.8) - (-0.2))

Z-scores and T-scores are expressed as (mean (CI 95%)) and significance is marked as * = p < 0.05, ** = <0.005 when compared to baseline and marked differently as ^# = p < 0.05, ^## = p < 0.005 when normal controls are compared to baseline data for patients with Graves' diseases or patients with Hashimoto's disease. NS = non-significant.

Belsing et al. Nutrition & Metabolism 2010 7:72   doi:10.1186/1743-7075-7-72